CMKLR1-Targeted Molecular Imaging of Inflammation as a Precision Medicine Tool in Acute Lung Injury and Fibrotic Lung Diseases

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Sina  Tavakoli
Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Fiscal Year: 2024
Award: $608,894
Funding agency: National Heart Lung and Blood Institute

ABSTRACT
Aberrant immune response to injury is a major pathogenic driver of adverse extracellular matrix remodeling after
acute lung injury (ALI) and a wide range of fibrotic lung diseases (referred to inflammation-fibrosis axis).
However, there is currently no established approach for noninvasive assessment of dysregulated lung
inflammation. This gap along with the pathophysiological heterogeneity and variability of the clinical course of
patients has hampered precision medicine management of fibrotic lung diseases. Chemokine-like receptor-1
(CMKLR1) is chemokine receptor which is overexpressed in profibrotic monocyte-derived macrophages, a
leukocyte subset with crucial roles in the pathogenesis of lung fibrosis. Our central goal is to determine the
potential of CMKLR1-targeted PET for i) quantitative imaging of lung inflammation; ii) prognostication of
the risk of disease progression; and iii) early monitoring of the response to anti-inflammatory and anti-
fibrotic interventions in experimental models of ALI and fibrotic lung injury. We will also address the clinical
relevance of CMKLR1-targeted PET and its potential for future clinical translation by determining the expression
of CMKLR1 in the lungs of patients with COVID-19 and several categories of fibrotic lung diseases vs. healthy
controls. Our preliminary data revealed a significant increase in lung uptake of a novel CMKLR1-targeted tracer
(64Cu-NODAGA-CG34) in two murine models of lipopolysaccharide-induced ALI and bleomycin-induced fibrotic
lung injury, which was primarily driven by the accumulation of monocyte-derived macrophages. Our central
hypothesis is that i) CMKLR1 serves as a biomarker of monocyte-derived macrophages in ALI and
fibrotic lung diseases; hence its targeted imaging by 64Cu-NODAGA-CG34 PET allows for ii) predicting
the risk of progression into sustained inflammation and fibrosis; and iii) monitoring the early therapeutic
response to anti-inflammatory and anti-fibrotic interventions. We propose three Specific Aims:
Specific Aim 1: To determine the immunoprofile of CMKLR1-expressing leukocytes in A) murine models of ALI
and fibrotic injury, and B) lung specimens of patients with COVID-19 and fibrotic lung diseases.
Specific Aim 2: To validate the accuracy of CMKLR1-targeted PET as a biomarker of inflammation at different
stages of ALI and fibrotic injury in murine models.
Specific Aim 3: To determine the potential of CMKLR1-targeted PET in A) disease prognostication; and B) early
detection of the therapeutic response in murine models of ALI and fibrotic lung injury.
Impact: By determining the role of CMKLR1-targeted PET for imaging macrophage-driven inflammation and
defining the expression of CMKLR1 across various fibrotic lung diseases, this proposal may lead to a precision
medicine strategy that allows for i) improved risk stratification; ii) prospective identification of patients with a high
likelihood of favorable response to anti-inflammatory/anti-fibrotic interventions (hence, sparing the others from
adverse effects and costs); & iii) personalized treatment adjustment based on early monitoring of the response.

Terms: <ARDS><Acute Lung Injury><Acute Pulmonary Injury><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Address><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Adverse effects><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Assay><Besnier-Boeck Disease><Bioassay><Biological><Biological Assay><Biological Markers><Bleo><Bleomycin><Blood Plasma><Blood leukocyte><Blood monocyte><Body Tissues><Boeck's Sarcoid><CAT scan><CHEMERINR><CHEMR23><CMKLR1><CMKLR1 gene><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 infected patient><COVID-19 patient><COVID-19 positive patient><COVID19 patient><COVID19 positive patient><CT X Ray><CT Xray><CT imaging><CT scan><CV-19><Categories><Cell-Extracellular Matrix><Chemerin Receptor><Chemokine Like Receptor 1><Chemokine Receptor Gene><Clinical><Computed Tomography><Coronavirus Infectious Disease 2019><Da Nang Lung><Data><Development><Dexamethasone><Diesel Exhaust><Disease><Disease Outcome><Disease Progression><Disease stratification><Disorder><ECM><Early Diagnosis><Esbriet><Experimental Models><Extracellular Matrix><Fibrosis><Fibrotic lesions in lung><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><Goals><Heterogeneity><Histologic><Histologically><Histology><Image><Immune response><Immunological response><Inflammation><Inflammatory><Injury><Interstitial Lung Diseases><Intervention><Intervention Strategies><Label><Leukocytes><Leukocytes Reticuloendothelial System><Ligands><Lipopolysaccharides><Lung><Lung Diseases><Lung Function Tests><Lung Inflammation><Lung Respiratory System><Lung Tissue Fibrosis><Lung damage><Lung scar><Lung tissue scar><Macrophage><Marrow leukocyte><Marrow monocyte><Mediating><Molecular Target><Monitor><Mφ><Occupational><Organ><PET><PET Scan><PET imaging><PETSCAN><PETT><Pathogenesis><Pathogenicity><Pathologic Processes><Pathological Processes><Patients><Pirfenidone><Plasma><Plasma Serum><Play><Pneumonitis><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Predicting Risk><Process><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary Inflammation><Pulmonary Scar><Pulmonary Tissue fibrosis><Pulmonary function tests><Rad.-PET><Research Specimen><Reticuloendothelial System, Serum, Plasma><Role><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><Sarcoidosis><Scarring at the lung><Scarring in the lung><Schaumann's Disease><Severities><Severity of illness><Shock Lung><Specimen><Stiff lung><Techniques><Tissues><Tomodensitometry><Tracer><Validation><Viral Pneumonia><White Blood Cells><White Cell><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><bio-markers><biologic><biologic marker><biomarker><catscan><chemokine receptor><cigarette smoke-induced><clinical relevance><clinical translation><clinically relevant><clinically translatable><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus infectious disease-19><coronavirus patient><cost><death risk><developmental><diagnostic approach><diagnostic strategy><disease of the lung><disease prognosis><disease prognostication><disease risk><disease severity><disorder of the lung><disorder risk><early detection><fibrosing interstitial lung disease><fibrosis in the lung><fibrotic interstitial lung disease><fibrotic lung><fibrotic lung disease><fibrotic pulmonary disease><flow cytophotometry><forecasting risk><host response><imaging><immune system response><immunoresponse><improved><individualized management><individualized patient management><inflammatory lung disease><injuries><injury response><interventional strategy><lung disorder><lung fibrosis><lung injury><molecular imaging><molecule imaging><monocyte><mortality risk><mouse model><murine model><new marker><non-contrast CT><noncontrast CT><noncontrast computed tomography><novel><novel biomarker><novel marker><overexpress><overexpression><particle><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient stratification><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><peptide mimetic><peptide mimic><peptidomimetics><personalization of treatment><personalized clinical management><personalized disease management><personalized management><personalized medicine><personalized therapy><personalized treatment><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><precision management><precision medicine><precision-based medicine><predict risk><predict risks><predicted risk><predicted risks><predicting risks><predictive risk><predicts risk><prognostication><progression risk><prospective><pulmonary><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><quantitative imaging><radiolabel><radiolabels><radiotracer><recruit><response><response to injury><response to therapy><response to treatment><risk prediction><risk predictions><risk stratification><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><social role><spatiotemporal><stratified patient><stratify risk><targeted imaging><therapeutic response><therapy response><tool><treatment response><treatment responsiveness><uptake><validations><wet lung><white blood cell><white blood corpuscle>